- Decrease font
- Increase font
- Send to a friend
Click here to bookmark this page
Customize your Bookmarks:
- Type the name of the page the way you would like it to appear in "My Bookmarks";
- Click in the "Add as My Bookmarks" button.
To choose your favorite sessions, please click here.
CENTRO DE IMAGEM DIAGNOSTICS S.A. ("Company". "Alliar") (B3: AALR3) ) in compliance with the provisions of the Securities and Exchange Commission ("CVM") Resolution No. 44, of August 23, 2021, as amended ("CVM Resolution 44") communicates to its shareholders and the market in general that, on April 8, 2022 and April 9, 2022, respectively, a notification sent by (i) the representatives of the shareholders of the Companys control block, signatories of the shareholders agreement signed on August 20, 2021, as amended ("Sellers") and (ii) by Fonte de Saúde Fundo de Investimento em Participações Multiestratégia ("Buyer") were received by the Company, for disclosure to the market, informing that, within the scope of the Companys share purchase and sale agreement, entered into on December 21, 2021 between Sellers and Buyer ("Agreement") : (i) on April 8, 2022, all suspensive conditions established in the Agreement were met; and (ii) the closing of the transaction must take place within 5 (five) business days from April 8, 2022.
The entire content of the Sellers Notice is contained as Attachment I to this Material Fact, while the entire content of the Buyers Notice is contained as Attachment II to this Material Fact.
The Company reiterates its commitment to keep the market informed about material facts and acts, in compliance with applicable regulations.
São Paulo, April 11, 2022.
To access the full document, click here.
CEO & IRO